Recent Updates
Recently added Catalysts
IRD

Ocuphire Pharma Announces Two Publications Supporting the APX3330 Program

Thursday, November 12, 2020 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ocuphire Pharma Announces Two Publications Supporting the APX3330 Program

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+140%
120-day peak, hindsight
Typical move
6.3%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
APX3330
Phase 2 · Diabetic Retinopathy

Full Press Release Details

Ocuphire Pharma Announces Two Publications Supporting the APX3330 Program.
ShareAdd on Google
Tags: IRD Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Nov 12, 2020

Biotech snapshot

Cash runway
$89M liquidity · $4M/mo burn
~22 mo
Low dilution risk
Lead asset
APX3330Phase 2
Diabetic Retinopathy →

Catalyst track record

+140%
best trade around IRD's most recent catalyst

Peak hindsight return over a 120-day window, across 11 tracked FDA/PDUFA catalysts for IRD.

See every catalyst's timing & PoA →